will medicare pay for semaglutide for weight loss the first time, cover GLP-1s obesity-related loss, without any other medical conditions. Starting Wednesday, eligible Medicare beneficiaries can receive GLP-1s for obesity for $50 per month by Medicare may finally cover weight

With diabetes and obesity cases surging in India, pharmaceutical giant Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a once-weekly injectable drug for chronic weight management and type 2 diabetes

The EPA first identified potential risks from the facilitys emissions in 2023

GLP-1, glucagon-like peptide1

Research studies on topical application typically report measurable skin parameter changes between 4 and 12 weeks

North America is dominating the GLP-1 analogues market, supported by a high prevalence of type 2 diabetes and obesity, strong healthcare infrastructure, and rapid adoption of innovative therapies